Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

Device and method for detection of prostate cancer in the surgical margin

Reference number
Coordinator Västerbottens läns landsting - Centrum för medicinsk teknik och strålningsfysik
Funding from Vinnova SEK 913 142
Project duration July 2016 - June 2018
Status Completed

Purpose and goal

The project has developed a multimodal instrument for the detection of cancer in the surgical margin associated with prostate cancer surgery so that the surgeon in real time can determine the extent of the surgical procedure for minimally left cancer in the surgical marginal. In this project, we conducted a risk analysis, market analysis, CE marking investigation, IPR analysis and conducted a verification study on ten human prostata. The instrument has been technically improved, the CE marking procedure documented, the IPR strategy developed and the verification study documented.

Expected results and effects

Market analysis shows a need and interests of the clinics as well as interest from investors to invest in the project, provided the plans are held. The instrument has been technically improved and a rotation arrangement has been developed to scan whole prostate. IPR analyzes yielded new ideas for further development of the instrument according to outcomes from the demand analysis. The verification study shows that the instrument can predict cancer in prostate tissue significantly but the Raman measurements are uncertain. The Raman instrument is now redesigned to overcome the problem.

Planned approach and implementation

The project has been carried out in collaboration between Västerbotten County Council (VLL), Umeå University (UMU) and Luleå Technical University (LTU). Umeå Biotech Incubator (UBI) has supported business development steps and the company MEDSENS AB owns the patent. The layout has worked very well and the competences have complemented each other perfectly (Technology, Pathology, Urology, Business Coach). The project´s finances have been managed by VLL, in collaboration with the other partie (LTU). The availability of prostate and histopathology analyzes has been a bottleneck.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 2 September 2019

Reference number 2016-02274

Page statistics